We evaluated the use of felbamate in 379 adults and children with refractory epilepsies in an open-label, compassionate clinical use setting. Prior to the termination of the program, because of reports of aplastic anemia, 351 patients had completed 2 months of treatment with felbamate at a dose of 2400-3600 mg/day for adults or 30-45 mg/kg/day for children. Of the 246 patients who had a diagnosis of therapy-refractory localization-related epilepsy with or without secondary generalization, 52% (126/246) achieved a seizure reduction of 50% or more, including 10% (25/246) who became seizure free. There was no difference in response rate between adults and children. Of the 80 patients who had a diagnosis of Lennox-Gastaut syndrome (LGS), 60% (48/80) achieved a seizure reduction of 50% or more, including 6% (5/80) who became seizure free. Of the 25 patients with a diagnosis of generalized epilepsy (other than LGS) or undetermined epilepsy whether focal or generalized, 60% (15/25) achieved a seizure reduction of 50% or more, including 12% (3/24) who became seizure free. The results of this uncontrolled study suggest that felbamate could be useful in patients with epilepsies which are refractory to other antiepileptic drugs after careful risk-benefit assessment and consideration of all circumstances involved.
Felbamate in therapy-resistant epilepsy: An Italian experience / Avanzini G.; Canger R.; Dalla Bernardina B.; Vigevano F.; Aguglia U.; Albano C.; Antonini L.; Battaglia S.; Battino D.; Benna P.; Besana D.; Antonelli C.; Binelli S.; Biondi R.; Boniver C.; Buti D.; Canziani F.; Capovilla G.; Casara G.; Casazza M.; Cernibori A.; Chindemi A.; Cianchetti C.; Cilio M.R.; Coppola G.; Cremonte M.; D'Agostino V.; Daniele O.; De Marco P.; De Maria G.; Di Cosmo F.; Di Perri R.; Durisotti C.; Elia M.; Fois A.; Fontana E.; Franceschetti S.; Gaggero R.; Galeone D.; Gallitto G.; Gianelli L.; Giovanardi Rossi P.; Giubergia S.; Gobbi G.; Guarneri B.; La Selva L.; Lanzi G.; Laurienzo P.; Lenti C.; Lunardi G.; Magaudda A.; Mangano S.; Marchini C.; Mecarelli O.; Michelucci R.; Muscas G.C.; Musetti L.; Musolino R.; Mutani R.; Parmeggiani A.; Pascotto A.; Pasquinelli A.; Pelliccia A.; Perniola T.; Pisani F.; Porta M.; Radice L.; Ricci G.F.; Ricci S.; Romeo A.; Rozza L.; Rozzi N.; Santucci M.; Sardella M.; Sasso E.; Severi S.; Sgro V.; Sofia V.; Specchio L.; Spreafico R.; Striano S.; Tassinari C.; Tiacci C.; Tiberti A.; Tinuper P.; Torelli D.; Tortorella G.; Valseriati D.; Veggiotti P.; Viani F.; Vignoli A.; Viri M.; Volpi L.; Zaccara G.; Zagnoni P.; Zambrino A.; Zappoli R.; Zucca C.; Zuddas A.. - In: EPILEPSY RESEARCH. - ISSN 0920-1211. - STAMPA. - 25:3(1996), pp. 249-255. [10.1016/S0920-1211(96)00070-8]
Felbamate in therapy-resistant epilepsy: An Italian experience
Giovanardi Rossi P.;Parmeggiani A.;Santucci M.;Tinuper P.;
1996
Abstract
We evaluated the use of felbamate in 379 adults and children with refractory epilepsies in an open-label, compassionate clinical use setting. Prior to the termination of the program, because of reports of aplastic anemia, 351 patients had completed 2 months of treatment with felbamate at a dose of 2400-3600 mg/day for adults or 30-45 mg/kg/day for children. Of the 246 patients who had a diagnosis of therapy-refractory localization-related epilepsy with or without secondary generalization, 52% (126/246) achieved a seizure reduction of 50% or more, including 10% (25/246) who became seizure free. There was no difference in response rate between adults and children. Of the 80 patients who had a diagnosis of Lennox-Gastaut syndrome (LGS), 60% (48/80) achieved a seizure reduction of 50% or more, including 6% (5/80) who became seizure free. Of the 25 patients with a diagnosis of generalized epilepsy (other than LGS) or undetermined epilepsy whether focal or generalized, 60% (15/25) achieved a seizure reduction of 50% or more, including 12% (3/24) who became seizure free. The results of this uncontrolled study suggest that felbamate could be useful in patients with epilepsies which are refractory to other antiepileptic drugs after careful risk-benefit assessment and consideration of all circumstances involved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
